| titleOfInvention |
FUSION PROTEIN, NUCLEIC ACID MOLECULE, HOST CELL, FUSION PROTEIN PRODUCTION METHOD, USE, METHOD OF ACTIVATING SIGNALING PATHWAYS, OF CO-ESTIMULATE T-CELLS, OF INDUCING LYMPHOCYTE ACTIVITY, OF INDUCING CD137 GROUPING, OF INDUCE A LYMPHOCYTE RESPONSE AND INDUCE AN INCREASE IN SECRETION, PHARMACEUTICAL COMPOSITION, AND METHOD OF PREVENTING, IMPROVING, OR TREATMENT PD-L1-POSITIVE CANCER |
| abstract |
“FUSION PROTEIN, ACID MOLECULEn NUCLEIC, HOST CELL, FUSION PROTEIN PRODUCTION METHOD,nUSE, METHOD OF ACTIVATING SIGNALING PATHWAYS, TO COESTIMULATE T CELLS,nTO INDUCE LYMPHOCYTE ACTIVITY, TO INDUCE THE GROUPING OF CD137, TOn INDUCE A LYMPHOCYTOSIS RESPONSE TO INDUCE AN INCREASE INnSECRETION, PHARMACEUTICAL COMPOSITION AND METHOD TO PREVENT, IMPROVE OR TREATn PD-L1-POSITIVE CANCERS. Disclosure provides fusion proteinsnspecific for CD137 and PD-L1, whose fusion protein can be usednto costimulate lymphocyte activation in a blood-dependent manner.nPD-L1 target. Such fusion proteins can be used in a variety ofnpharmaceutical applications, for example as anti-cancer agents and/ornimmune modulators for the treatment or prevention of diseasenhumans, such as a variety of tumors. This disclosure alson concerns methods for producing the fusion proteins herendescribed, as well as compositions comprising such fusion proteins. THEn The present disclosure further relates to nucleic acid moleculesnencoding such fusion proteins and methods for generatingnsuch fusion proteins and nucleic acid molecules. In addition, thenThe present application describes therapeutic and/or diagnostic uses ofn such fusion proteins, as well as compositions comprising one or moren of these fusion proteins. |